Categories
Change Password!
Reset Password!
This phase 4 randomized controlled trial explored the safety and efficacy of incorporating nitazoxanide as an adjunct to the standard clarithromycin-based regimen for Helicobacter pylori (H. pylori) management.
Adding nitazoxanide to standard clarithromycin-based therapy significantly boosts eradication rates of H. pylori.
This phase 4 randomized controlled trial explored the safety and efficacy of incorporating nitazoxanide as an adjunct to the standard clarithromycin-based regimen for Helicobacter pylori (H. pylori) management.
Overall, 200 treatment-naïve patients positive for H. pylori were randomly assigned into 4 groups:
All treatments were given for 14 days, and patients were evaluated 4 weeks post-therapy.
The addition of nitazoxanide to standard clarithromycin-based triple therapy resulted in a high eradication rate: 84% by intention-to-treat analysis and 89.36% by per-protocol analysis, with a statistically significant p-value of 0.01.
Nitazoxanide-based quadruple regimen proved to be both effective and safe, supporting its potential use as a first-line treatment for H. pylori elimination.
Journal of Infection in Developing Countries
Efficacy and safety of nitazoxanide based quadruple regimen as first line therapy for treating Helicobacter pylori infected naïve patients
Amro M Hassan et al.
Comments (0)